This company has been marked as potentially delisted and may not be actively trading. Intra-Cellular Therapies (ITCI) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for ITCI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors. Enter your email to sign up for newsletter Sign Up ITCI Analyst Ratings Over TimeTypeCurrent Forecast7/24/24 to 7/24/251 Month Ago6/24/24 to 6/24/253 Months Ago4/25/24 to 4/25/251 Year Ago7/25/23 to 7/24/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)2 Buy rating(s)10 Buy rating(s)Hold10 Hold rating(s)10 Hold rating(s)10 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$109.70$109.70$109.70$94.83Forecasted Upside-16.81% Downside-16.81% Downside-16.81% Downside22.73% UpsideConsensus RatingHoldHoldHoldModerate Buy ITCI Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ITCI Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Intra-Cellular Therapies Stock vs. The CompetitionTypeIntra-Cellular TherapiesMedical CompaniesS&P 500Consensus Rating Score 2.17 2.81 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-16.81% Downside8,234.61% Upside9.38% UpsideNews Sentiment RatingNeutral NewsSee Recent ITCI NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails4/2/2025Cantor Fitzgerald4 of 5 starsC. DuncanSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00+0.07%2/24/2025Mizuho3 of 5 starsGraig SuvannavejhSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.00+2.64%2/21/2025Needham & Company LLC2 of 5 starsA. FadiaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold1/31/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSumant KulkarniSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$119.00 ➝ $132.00+3.94%1/22/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$108.00 ➝ $132.00+3.61%1/14/2025Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDavid AmsellemSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$107.00 ➝ $132.00+3.89%1/13/2025Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingM. GoodmanSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold1/13/2025Baird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. BeattySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold11/4/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$81.00 ➝ $89.00+2.84%10/11/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$92.00 ➝ $95.00+25.02% Get the Latest News and Ratings for ITCI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. 8/8/2024UBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. VermaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetNeutral ➝ Neutral$83.00 ➝ $79.00+7.61%8/8/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$77.00 ➝ $74.00+0.50%4/17/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$80.00 ➝ $90.00+15.05%4/17/2024Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform ➝ Outperform$83.00 ➝ $103.00+31.66%4/17/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$82.00 ➝ $91.00+16.32%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:25 AM ET. ITCI Forecast - Frequently Asked Questions What is Intra-Cellular Therapies' forecast for 2025? According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Intra-Cellular Therapies is $109.70, with a high forecast of $132.00 and a low forecast of $74.00. Should I buy or sell Intra-Cellular Therapies stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ITCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITCI, but not buy additional shares or sell existing shares. Does Intra-Cellular Therapies's stock price have much downside? According to analysts, Intra-Cellular Therapies's stock has a predicted downside of -16.81% based on their 12-month stock forecasts. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors? Analysts like Intra-Cellular Therapies less than other "medical" companies. The consensus rating for Intra-Cellular Therapies is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ITCI compares to other companies. Stock Forecasts and Research Tools Related Companies TAK Stock Forecast ARGX Stock Forecast ONC Stock Forecast BNTX Stock Forecast SMMT Stock Forecast INSM Stock Forecast TEVA Stock Forecast GMAB Stock Forecast MRNA Stock Forecast RDY Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ITCI) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
